Going forward, more efforts need to be made to understand the influence of p53 on responses to Chk1/Wee1 inhibitors with radiation in both tumour and normal tissues, with a view to decreasing any potential adverse side effects of the treatment and increasing the therapeutic ratio. The gene discussed is TP53; the disease is neoplasm.